VolitionRx Ltd. (NYSE American: VNRX), a multinational epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by Hospices Civils de Lyon (HCL), France’s second-largest university hospital system, and will run in parallel with the previously announced clinical certification process at HCL.
HCL researchers indicated that the Nu.Q® Cancer test is intended to be introduced into routine, reimbursed clinical practice for lung cancer management in France following the completion of the reimbursement and certification processes. Data generated through collaboration with Volition suggest that measuring methylated nucleosome biomarkers at the time of non-small cell lung cancer diagnosis can provide information related to survival and disease progression. This approach may also help identify patients who could benefit from curative care.
Volition stated that the reimbursement submission is expected to be filed under France’s “Innovative Procedures Outside the Nomenclature” framework, which allows early reimbursement support for innovative medical procedures. The company noted that reimbursement would represent a major milestone toward routine clinical use of Nu.Q® Cancer assays in France and support broader commercialization and potential licensing discussions in other markets.
For more details, the full press release is available at https://ibn.fm/qxNIy.
Volition is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, Volition is developing and commercializing simple, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
This development is significant because successful reimbursement in France could accelerate the adoption of Nu.Q Cancer assays in clinical practice, potentially improving lung cancer management and patient outcomes. It also paves the way for expansion into other markets.
